Stocktoria
Core Scientific, Inc./tx CORZ
Nasdaq · stock · Finance Services · website · IPO 2021-04-05
Core Scientific, Inc./tx financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $319.0M | $510.7M | $502.4M | $640.3M | $544.5M | $60.3M |
| Gross profit | $37.9M | $121.1M | $123.5M | $8.4M | $238.9M | $9.4M |
| R&D expense | — | $11.8M | $7.2M | $27.0M | $7.7M | $5.3M |
| SG&A expense | $159.2M | $113.7M | $108.1M | — | — | — |
| Operating income | -$245.6M | -$142.1M | $9.0M | -$2.1B | $131.5M | -$6.3M |
| Income tax | $583,000 | $859,000 | $683,000 | -$17.1M | $15.8M | $0 |
| Net income | -$288.6M | -$1.4B | -$246.5M | -$2.1B | $47.3M | -$12.2M |
| EPS (diluted) | $-0.88 | $-4.87 | $-0.65 | $-6.30 | $0.20 | $-0.14 |
| Operating cash flow | $278.2M | $42.9M | $65.1M | $205.2M | -$56.7M | -$23.8M |
| Free cash flow | -$450.8M | -$52.1M | $49.0M | -$178.8M | -$56.7M | -$23.8M |
| Cash & equivalents | $311.4M | $836.2M | $50.4M | $15.9M | $117.9M | — |
| Total assets | $2.3B | $1.5B | $712.2M | $807.7M | $2.4B | $15,000 |
| Total liabilities | $3.3B | $2.4B | $1.3B | $1.2B | $1.1B | $400 |
| Shareholders' equity | -$962.7M | -$943.0M | -$596.9M | -$409.3M | $1.3B | $89.2M |
Growth · year-over-year · Revenue CAGR 39.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -37.5% | +1.6% | -21.5% | +17.6% | +802.7% | — |
| Net income growth | — | — | — | -4636.5% | — | — |
| EPS growth | — | — | — | -3250.0% | — | — |
| Free cash flow growth | — | -206.4% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.